



This is a repository copy of *Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 1; peer review: 2 approved]*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/197285/>

Version: Published Version

---

**Article:**

Jarju, S. [orcid.org/0000-0003-2621-8406](https://orcid.org/0000-0003-2621-8406), Senghore, E., Brotherton, H. et al. (19 more authors) (2022) Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 1; peer review: 2 approved]. *Gates Open Research*, 6. 148. ISSN 2572-4754

<https://doi.org/10.12688/gatesopenres.14155.1>

---

**Reuse**


This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



## RESEARCH ARTICLE

# Circulation of respiratory viruses during the COVID-19

## pandemic in The Gambia [version 1; peer review: 2 approved]

Sheikh Jarju <sup>1</sup>, Elina Senghore<sup>1</sup>, Helen Brotherton<sup>1</sup>, Alasana Saidykhan<sup>1</sup>, Samba Jallow<sup>1</sup>, Edrissa Krubally<sup>1</sup>, Edrisa Sinjanka<sup>1</sup>, Morris Ngor Ndene<sup>1</sup>, Fabakary Bajo<sup>1</sup>, Musa M Sanyang<sup>1</sup>, Binta Saidy<sup>1</sup>, Alasana Bah <sup>1</sup>, Nuredin I Mohammed<sup>1</sup>, Karen Forrest <sup>1</sup>, Ed Clarke<sup>1</sup>, Umberto Dalessandro<sup>1</sup>, Abdul K Sesay<sup>1</sup>, Effua Usuf<sup>1</sup>, Carla Cerami <sup>1</sup>, Anna Roca<sup>1,2</sup>, Beate Kampmann<sup>1,3</sup>, Thushan I de Silva<sup>1,3,4</sup>

<sup>1</sup>Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, P.O.BOX 273, The Gambia

<sup>2</sup>Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK

<sup>3</sup>The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK

<sup>4</sup>4. Department of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

**V1** First published: 08 Dec 2022, 6:148  
<https://doi.org/10.12688/gatesopenres.14155.1>  
 Latest published: 16 Feb 2023, 6:148  
<https://doi.org/10.12688/gatesopenres.14155.2>

### Abstract

**Background:** In many countries, non-pharmaceutical interventions to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission resulted in significant reductions in other respiratory viruses. However, similar data from Africa are limited. We explored the extent to which viruses such as influenza and rhinovirus co-circulated with SARS-CoV-2 in The Gambia during the COVID-19 pandemic.

**Methods:** Between April 2020 and March 2022, respiratory viruses were detected using RT-PCR in nasopharyngeal swabs from 1397 participants with influenza-like illness. An assay to detect SARS-CoV-2 and a viral multiplex RT-PCR assay was used as previously described to detect influenza A and B, respiratory syncytial virus (RSV) A and B, parainfluenza viruses 1-4, human metapneumovirus (HMPV), adenovirus, seasonal coronaviruses (229E, OC43, NL63) and human rhinovirus.

**Results:** Overall virus positivity was 44.2%, with prevalence higher in children <5 years (80%) compared to children aged 5-17 years (53.1%), adults aged 18-50 (39.5%) and >50 years (39.9%),  $p < 0.0001$ . After SARS-CoV-2 (18.3%), rhinoviruses (10.5%) and influenza viruses (5.5%) were the most prevalent. SARS-CoV-2 positivity was lower in children <5 (4.3%) and 5-17 years (12.7%) than in adults aged 18-50 (19.3%) and

### Open Peer Review

#### Approval Status

	1	2
<b>version 2</b> (revision) 16 Feb 2023		
<b>version 1</b> 08 Dec 2022	 view	 view

1. **Ivy A. Asante** , University of Ghana, Accra, Ghana

2. **Antonia Ho** , University of Glasgow, Glasgow, UK


Any reports and responses or comments on the article can be found at the end of the article.

>50 years (24.3%),  $p < 0.0001$ . In contrast, rhinoviruses were most prevalent in children <5 years (28.7%), followed by children aged 5-17 (15.8%), adults aged 18-50 (8.3%) and >50 years (6.3%),  $p < 0.0001$ . Four SARS-CoV-2 waves occurred, with 36.1%-52.4% SARS-CoV-2 positivity during peak months. Influenza infections were observed in both 2020 and 2021 during the rainy season as expected (peak positivity 16.4%-23.5%). Peaks of rhinovirus were asynchronous to the months when SARS-CoV-2 and influenza peaked.

**Conclusion:** Our data show that many respiratory viruses continued to circulate during the COVID-19 pandemic in The Gambia, including human rhinoviruses, despite the presence of NPIs during the early stages of the pandemic, and influenza peaks during expected months.

### Keywords

SARS-CoV-2, respiratory viruses, surveillance, Influenza like illness



This article is included in the [Coronavirus \(COVID-19\)](#) collection.

**Corresponding author:** Thushan I de Silva ([t.desilva@sheffield.ac.uk](mailto:t.desilva@sheffield.ac.uk))

**Author roles:** **Jarju S:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Senghore E:** Data Curation, Investigation, Methodology; **Brotherton H:** Investigation, Methodology, Supervision; **Saidykhan A:** Data Curation, Investigation, Project Administration; **Jallow S:** Data Curation, Investigation, Project Administration; **Krubally E:** Data Curation, Investigation, Project Administration; **Sinjanka E:** Data Curation, Investigation, Project Administration; **Ndene MN:** Data Curation, Investigation; **Bajo F:** Data Curation, Investigation; **Sanyang MM:** Data Curation, Investigation; **Saidy B:** Formal Analysis, Software; **Bah A:** Data Curation, Investigation, Project Administration; **Mohammed NI:** Visualization; **Forrest K:** Conceptualization, Investigation, Supervision, Visualization; **Clarke E:** Conceptualization, Investigation, Supervision, Visualization; **Dalessandro U:** Conceptualization, Investigation, Visualization; **Sesay AK:** Conceptualization, Investigation, Visualization; **Usuf E:** Conceptualization, Investigation, Visualization; **Cerami C:** Conceptualization, Investigation, Methodology, Supervision, Visualization, Writing – Original Draft Preparation; **Roca A:** Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Visualization, Writing – Original Draft Preparation; **Kampmann B:** Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **de Silva TI:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The study was funded by the Bill and Melinda Gates Foundation (INV-015823), a Global Challenge Research Fund award from The University of Sheffield, UK, MRCG Vaccines and Immunity core funding (MC\_UP\_A900/1122), and PaTS trial funding from a UK Research and Innovation grant (MC\_PC\_19084).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2022 Jarju S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Jarju S, Senghore E, Brotherton H *et al.* **Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 1; peer review: 2 approved]** Gates Open Research 2022, 6:148 <https://doi.org/10.12688/gatesopenres.14155.1>

**First published:** 08 Dec 2022, 6:148 <https://doi.org/10.12688/gatesopenres.14155.1>

## Introduction

Many countries reported a dramatic reduction in the circulation of common respiratory viruses such as influenza and respiratory syncytial virus (RSV) during the initial stages of the COVID-19 pandemic<sup>1-3</sup>. This was attributed to the multiple non-pharmaceutical interventions (NPIs) implemented to reduce SARS-CoV-2 transmission such as bans on travel and social interactions, school closures, and mandatory wearing of face masks. Many of these early studies are from high-income countries with temperate climates, where the transmission patterns and seasonality of influenza and other respiratory viruses are well established<sup>1-3</sup>. In West Africa, surveillance for respiratory viruses is limited and data on the circulation of influenza and other viruses during the COVID-19 pandemic scarce.

The Gambia reported its first COVID-19 case on the 17<sup>th</sup> March 2020 in a traveller<sup>4</sup>. A state of public emergency was declared on 27<sup>th</sup> March 2020: NPIs such as social distancing, borders closure, closure of schools, ban on public gatherings, a night-time curfew, and compulsory wearing of face masks in public places were implemented. No increase in SARS-CoV-2 cases were seen in The Gambia until June 2020, when the first wave of infections occurred<sup>5</sup>. The state of emergency was relaxed on the 17<sup>th</sup> September 2020 and since then, NPIs have not been enforced. Nevertheless, three further SARS-CoV-2 waves have occurred in The Gambia up to March 2022<sup>5</sup>.

We conducted a surveillance of respiratory viruses, including SARS-CoV-2, between April 2020 and March 2022. Our objectives were to describe the extent to which other respiratory viruses circulated alongside SARS-CoV-2 in The Gambia during the study period, whether there were differences in the prevalence of SARS-CoV-2 and other respiratory viruses across age groups, and whether peaks of other viruses such as human rhinovirus occurred at the same time or asynchronously with SARS-CoV-2.

## Methods

### Study setting, participant recruitment and sample collection


The Gambia has a population of approximately 2.5 million, with more than half living in urban coastal areas<sup>6</sup>. The climate is subtropical with a short rainy season between June

and October, and a long dry season for the rest of the year<sup>7</sup>. Average temperatures range between 23°C to 33°C during the rainy season, and between 18°C to 30°C during the dry season<sup>7</sup>. Knowledge of influenza virus circulation is limited but coincided with the rainy season in a 12-month surveillance study<sup>8</sup>. No routine influenza vaccination programme is in place in The Gambia. SARS-CoV-2 vaccination of adults commenced in March 2021.

Nasopharyngeal swabs (NPS) from two surveillance studies were used for this analysis. In both studies, we received written consent from participants. Where the participants were children, consent was sought from parents/guardians and assent of the subject. In the first study, influenza-like illness (ILI) surveillance samples were collected from adults and children of all ages with acute respiratory illnesses attending the outpatient medical services at the Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine (MRCG@LSHTM) clinics in Fajara (urban, coastal) and Keneba (rural) as shown in [Figure 1](#). Patients presenting with shortness of breath, cough, or history of fever of any severity within the last 10 days provided written informed consent prior to study recruitment. Sample collection was carried out between April 2020 and June 2021 in Fajara and between September 2020 and June 2021 in Keneba.

In the second study, samples were collected between January 2021 and March 2022 from a clinical trial on COVID-19 treatment conducted in urban and peri-urban areas from sites shown in [Figure 1](#) (Brikama, Bundung, Bakau and Fajara), the PaTS study; Prevention and Treatment for Covid-19 associated severe pneumonia in The Gambia: a Randomized Clinical Trial (NCT04703608). At screening, written informed consent was obtained from potential participants aged  $\geq 5$  years presenting with acute fever and cough, or three or more of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia/nausea/vomiting, diarrhoea, recent loss of smell, recent loss of taste, altered mental status. Data on self-reported sex, or in the case of children, parent-reported sex, was also collected.

Both studies were approved by the Gambia Government and MRCG joint ethics committee and the Research Ethics



**Figure 1.** A map of The Gambia showing sites where participants were recruited for the two studies. The PaTS study sites were in Brikama, Bundung, Bakau and Fajara. The influenza-like illness (ILI) study sites were in Keneba and Fajara.

Committee at the London School of Hygiene and Tropical Medicine (LSHTM).

**Respiratory virus detection**

Ribonucleic acid (RNA) was extracted from 200µL of universal transport medium from NPS using the QIAamp Viral RNA kit (QIAGEN, Germany) as per the manufacturer’s instructions. All samples were spiked with Phocine herpes virus (PhHV) prior to extraction as a quality control for RNA extraction efficiency.

SARS-CoV-2 was detected using a Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), with either the Takara One Step PrimeScript III RT-PCR Kit (TaKaRa Bio Inc., Japan, catalogue number RR600A) or the SuperScript III Platinum One-Step qRT-PCR Kit (Invitrogen, USA, catalogue number 11732-088). Primers and probes targeting SARS-CoV-2 E and N genes, along with RNase P and PhHV were used previously described<sup>4</sup>. Samples were considered positive if all four gene targets amplified at a cycle threshold (Ct) of 37 or below. In addition, a viral multiplex RT-PCR assay was used as previously described<sup>8</sup> to detect influenza A and B, respiratory syncytial virus (RSV) A and B, parainfluenza viruses 1–4, human metapneumovirus (HMPV), adenovirus, seasonal coronaviruses (229E, OC43, NL63) and human rhinovirus. All samples with a Ct of ≤37 and passed quality control measures were considered positive.

**Data analysis**

Clinical data, demographics and RT-PCR results were entered on a REDCap database. All results and metadata were

downloaded from the database and analysed using Graphpad Prism V9.1.2 or Microsoft Excel. Statistical comparisons between group proportions were carried out using the two-sided chi-squared or Fisher’s exact test.

**Results**

Among the 1397 participants recruited between April 2020 and March 2022, 617 (44.2%) were positive for one or more respiratory viruses. Virus positivity was significantly higher in children <5 years (80.0%, 95% CI 71.9-86.9%) than in the other age groups: children aged 5–17 years (53.1%, 45.1-61.1%), adults aged 18–50 years (39.5%, 36.2-42.9%), and adults >50 years (39.9%, 34.0-46.1%), p<0.0001 (Table 1).

Overall, 255 (18.3%, 16.3-20.4%) of samples tested during the study period were positive for SARS-CoV-2 (Table 2). The next most prevalent viruses were human rhinovirus (10.5%, 8.9-12.2%) and influenza A or B (5.5%, 4.4-6.8%). SARS-CoV-2 positivity was lower among children <5 years (4.3%, 1.4-9.9%) than in children aged 5–17 years (12.7%, 7.9-18.9%), adults aged 18–50 (19.3%, 16.7-22.1%), and adults >50 years (24.3%, 19.3-29.8%), p<0.0001. In contrast, human rhinovirus infections were most prevalent in children aged <5 years (28.7%, 20.7-37.9%), than in children aged 5–17 years (15.8%, 10.5-22.3%), adults aged 18–50 (8.3%, 6.5-10.4%), and adults >50 years (6.3%, 3.7-10.0%), p<0.0001. Most RSV A and HMPV infections were detected in children <5 years old, although the number of cases was relatively low (Table 2). The prevalence of respiratory viruses within each age group across the different study sites is shown in Tables S1-S3.

**Table 1. Recruited participants and percentage with respiratory viruses detected stratified by recruitment site, age and sex.** Total numbers are shown with % in brackets. The denominators for age and sex percentages are the total recruited numbers at each site or all participants combined. Virus positivity denotes detection of one or more viruses in the sample. The denominators for respiratory virus positive % are the total recruited within each sex or age strata for each study or all participants combined. The PaTS trial did not recruit any children below the age of 5 years.

		Fajara (n=611) (Apr 2020–Jun 2021)		Keneba (n=337) (Sep 2020–Jun 2021)		PaTS (n=449) (Jan 2021–Mar 2022)		All sites (n=1397) Apr 2020 – Mar 2022	
		Recruited participants	Virus positivity	Recruited participants	Virus positivity	Recruited participants	Virus positivity	Recruited participants	Virus positivity
Sex	Male	308 (50.4)	109 (35.4)	139 (41.2)	92 (66.2)	200 (44.5)	88 (44.0)	<b>647 (46.3)</b>	<b>289 (44.7)</b>
	Female	303 (49.6)	108 (35.6)	198 (58.8)	112 (56.6)	249 (55.5)	108 (43.4)	<b>750 (53.7)</b>	<b>328 (43.7)</b>
Age	< 5 years	50 (8.2)	30 (60.0)	65 (19.3)	57 (87.7)	0 (0.0)	0 (0.0)	<b>115 (8.3)</b>	<b>92 (80.0)</b>
	5–17 years	43 (7.0)	16 (37.2)	51 (15.1)	36 (70.6)	64 (14.3)	32 (50.0)	<b>158 (11.3)</b>	<b>84 (53.1)</b>
	18–50 years	401 (65.6)	134 (33.4)	145 (43.0)	77 (53.1)	310 (69.0)	127 (41.0)	<b>856 (61.2)</b>	<b>338 (39.5)</b>
	>50 years	117 (19.2)	37 (31.6)	76 (22.6)	34 (44.7)	75 (16.7)	36 (48.0)	<b>268 (19.2)</b>	<b>107 (39.9)</b>

**Table 2. Respiratory viruses detected during the study period stratified by age of participants.**

Respiratory viruses detected during the study period stratified by age of participants. The denominator for virus positivity is total participants in the study (n=1397) or the number of participants recruited in each age group. RSV A = Respiratory Syncytial Virus A; HMPV = Human Metapneumovirus; HPIV = Human Parainfluenza viruses (pooled samples positive for HPIV1-4); Seasonal Coronavirus = combined 229E, NL63 and OC43 positive samples. Influenza A = samples positive for influenza A but negative in the pandemic H1N1 specific assay, which are presumed Influenza A H3N2, but not confirmed.

	Virus positivity (%)	<5 years	5–17 years	18–50 years	>50 years
<b>SARS-CoV-2</b>	255 (18.3)	5 (4.3)	20 (12.7)	165 (19.3)	65 (24.3)
<b>Human Rhinovirus</b>	146 (10.5)	33 (28.7)	25 (15.8)	71 (8.3)	17 (6.3)
<b>Influenza (all)</b>	77 (5.5)	10 (8.7)	15 (9.5)	42 (4.9)	10 (3.7)
Influenza A	29 (2.1)	4 (3.5)	7 (4.4)	12 (1.4)	6 (2.2)
Influenza A (H1N1)	10 (0.7)	0 (0.0)	2 (1.3)	8 (0.9)	0 (0.0)
Influenza B	38 (2.7)	6 (5.2)	6 (3.8)	22 (2.6)	4 (1.5)
<b>HPIV</b>	47 (3.4)	9 (7.8)	8 (5.1)	22 (2.6)	8 (3.0)
<b>HMPV</b>	38 (2.7)	14 (12.2)	9 (5.7)	13 (1.5)	2 (0.8)
<b>RSV A</b>	25 (1.8)	14(12.2)	2 (1.3)	9 (1.1)	0 (0.0)
<b>Seasonal Coronavirus</b>	26 (1.9)	2 (1.7)	4 (2.5)	15 (1.8)	5 (1.9)
<b>Adenovirus</b>	2 (0.1)	0 (0.0)	1 (0.6)	1 (0.1)	0 (0.0)
<b>Samples tested</b>	1397	115	158	856	268


Only 2.9% (41/1397) of recruited participants were hospitalized for their illness, although details of the clinical reasons for admission were not available. 15 (36.6%) of these admissions had respiratory viruses detected in NPS (3 RSV A, 3 Influenza B, 2 HMPV, 3 parainfluenza virus 1 and 4 human rhinovirus). 36.6% (15/41) of hospitalizations were in children <5 years old, representing a 13.0% (15/115) admission rate in this age group compared to 2.0% in the other age groups (26/1282),  $p < 0.0001$ .

Four SARS-CoV-2 waves were observed in The Gambia during the 24-month study period (Figure 2); two during the rainy season (peak detection August 2020 and July 2021) and two during the dry season (peak detection March 2021 and January 2022). SARS-CoV-2 positivity during the four waves were 45.7%, 36.1%, 52.4% and 41.4%, respectively. Influenza A infections peaked in October 2020 (16.4% positivity) and October 2021 (23.5% positivity), with influenza B infections detected only in 2020 (peak November 2020, 23.3% positivity, Figure 2). Despite asynchronous peaks of SARS-CoV-2 and influenza, co-infections were observed, with 4/39 (10.3%) influenza A and 8/38 (21.1%) influenza B infected individuals also tested positive for SARS-CoV-2. 12.0% (3/25) of RSV A infections, 10.5% (4/38) of HMPV infections, 6.4% (3/47) of parainfluenza virus infections, and 4.1% (6/146) of human rhinovirus infections were also positive for SARS-CoV-2. Human rhinovirus positivity usually peaked at different times than SARS-CoV-2 and influenza (Figure 2). The prevalence of respiratory viruses over time stratified by study site is shown in Figure S1.

## Discussion

SARS-CoV-2 was the most prevalent respiratory virus found among patients presenting with ILI during the COVID-19 pandemic in The Gambia. Although the seasonality of respiratory viruses is less predictable in tropical and sub-tropical than in temperate regions, many viral infections including influenza peak during the rainy season in The Gambia and neighbouring Senegal<sup>8,9</sup>. It is still unclear whether SARS-CoV-2 transmission will become seasonal, but The Gambia has experienced waves of infection in both the rainy and the dry season so far (twice per year), likely reflecting the emergence of new variants globally. Of note, the SARS-CoV-2 dynamics we have observed occurred in the context of no NPIs after the first wave and only 13.1% of the Gambian population fully vaccinated by February 2022<sup>10</sup>.

We observed peaks in influenza activity in October during 2020 and 2021, although without robust surveillance data from previous years, it is difficult to determine whether there was a reduction in transmission. Our previous study in children <5 years old with ILI attending outpatient services in Fajara found 8.4% influenza A or B positivity over 12 months in 2018–19<sup>8</sup>, compared to 7.3% in our current study which included both adults and children. In Senegal, between 1996 and 2009, 10.4% samples were positive for influenza A and 2.9% for influenza B<sup>9</sup>. Even in the absence of formal NPIs, either behavioural changes or reduction in global influenza transmission leading to reduced introductions could have an impact on influenza infections in The Gambia. However, the dramatic reductions in influenza seen in many high-income countries with strictly



**Figure 2. Percentage of influenza-like illness cases positive for respiratory viruses in The Gambia during April 2020 – March 2022.** Vertical grey bars indicate the number of samples tested per month. Date when COVID-19 pandemic state of emergency was lifted is shown, after which time no restrictions or non-pharmaceutical interventions were in place within the country. Horizontal grey bars under the graph show periods when sample collection was done in the three participating sites (Fajara, Keneba, PaTS Study). Surveillance in Fajara was carried out between April 2020 and June 2021. Surveillance in Keneba was carried out between September 2020 and June 2021. Sample collection in the PaTS study was between January 2021 and March 2022. RSV A = Respiratory Syncytial Virus A; HMPV = Human Metapneumovirus; HPIV = Human Parainfluenza viruses (pooled samples positive for HPIV1-4); Seasonal Coronavirus = combined 229E, NL63 and OC43 positive samples. Influenza A = samples positive for influenza A but negative in the pandemic H1N1 specific assay.

enforced NPIs do not appear to have occurred in The Gambia<sup>1-3</sup>. This may in part be due to poor adherence to NPIs, even when these measures were in place. In Canada, the average weekly positivity rate for influenza A in 2020–2021 was 0.012% compared to 10.40% in pre-pandemic years, and 0.006% for influenza B compared to 2.60% in pre-pandemic years<sup>1</sup>. Data from other African countries are scarce, with influenza and RSV reductions observed in South Africa<sup>11</sup>, but not in the Democratic Republic of the Congo (5.6% influenza A positivity and 0.9% influenza B positivity Dec 2020 – March 2021)<sup>12</sup>.

After SARS-CoV-2, human rhinovirus was the most prevalent virus detected in our samples. As expected, SARS-CoV-2 was responsible for a lower proportion of symptomatic ILI syndromes in children compared to adults, and the reverse pattern was seen for rhinovirus infections with decreasing prevalence with increasing age. Persistent circulation of human rhinoviruses has been described during the COVID-19 pandemic even in countries with NPI-driven reductions in other respiratory viruses, especially in the context of the

reopening of schools<sup>1,13</sup>. This was also evident in our data with rhinoviruses circulating during the only period of NPI enforced in The Gambia, although schools were closed during that period. The high prevalence of human rhinovirus infections in children and the resulting increases in upper respiratory tract infections have been proposed as a potential mechanism for the reduced severity of COVID-19 observed in children<sup>14,15</sup>. The shared mucosal niche provides the opportunity for viral-viral interactions and interference between influenza and human rhinoviruses has been demonstrated in both epidemiological and *in vitro* data<sup>16,17</sup>. Whether similar interference between rhinoviruses and SARS-CoV-2 occurs to a degree population level transmission dynamics of either virus are affected is currently unclear. Our data on rhinovirus peaks and troughs during the study period should be treated with caution due to the small sample size and lack of pre-pandemic annual rhinovirus circulation patterns. Nevertheless, our findings do suggest that asynchronous circulation of SARS-CoV-2 and rhinoviruses may occur, supporting the experimental data from recent studies<sup>14,15</sup>.

This study has few limitations that need to be considered when interpreting our findings. The data come from two different studies with slightly different entry criteria, as well as different periods of participant recruitment. The main reasons for combining data from the two studies were to increase the sample size to enhance power and observe respiratory virus prevalence across a longer time period with which to arrive at more robust conclusions about seasonality. The PaTS trial did not recruit children under 5 years old, however, we show age stratified data to demonstrate any differences in respiratory virus prevalence across age groups. The PaTS trial also had a broader list of symptoms in the inclusion criteria. However, 454/484 (93.8%) participants included in the PaTS study had a history of fever or cough, therefore would have been recruited according to the ILI study inclusion criteria.

In summary, our data show that many respiratory viruses continued to circulate during the COVID-19 pandemic in The Gambia, including human rhinoviruses, despite the presence of NPIs during the early stages of the pandemic, and influenza peaks during expected months. The age distributions of SARS-CoV-2 and human rhinovirus prevalence in symptomatic ILI are diametrically opposite, with rhinovirus infections driving the greater respiratory virus positivity seen in young children. The degree to which virus-virus interactions shape the impact of future SARS-CoV-2 waves and seasonality is important to establish as the transition to endemicity occurs in the coming years.

## Consent

Written informed consent for publication of the participants/patients' details was obtained from the participants/patients/parents/guardian/relative of the participant/patient.

## References

- Groves HE, Piché-Renaud PP, Peci A, *et al.*: **The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study.** *Lancet Reg Health Am.* 2021; **1**: 100015.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Huang QS, Wood T, Jelley L, *et al.*: **Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand.** *Nat Commun.* 2021; **12**(1): 1001.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sullivan SG, Carlson S, Cheng AC, *et al.*: **Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020.** *Euro Surveill.* 2020; **25**(47): 2001847.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Abatan B, Agboghoroma O, Akemoke F, *et al.*: **Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia.** *Emerg Infect Dis.* 2021; **27**(8): 2064–72.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- <https://ourworldindata.org/explorers/coronavirus-data-explorer> Accessed 19th July 2022.
- Demographics G: **Gambia Demographics.** 2020 (Population, Age Sex, Trends) - Worldometer [Internet]. 2020; [cited 2022 Mar 10].  
[Reference Source](#)
- Access Gambia: **Gambia Climate.** 2021; [cited 2022 Mar 8].  
[Reference Source](#)
- Jarju S, Greenhalgh K, Wathuo M, *et al.*: **Viral Etiology, Clinical Features and Antibiotic Use in Children <5 Years of Age in the Gambia Presenting With Influenza-like Illness.** *Pediatr Infect Dis J.* 2020; **39**(10): 925–30.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Niang MN, Dosseh A, Ndiaye K, *et al.*: **Sentinel surveillance for influenza in Senegal, 1996–2009.** *J Infect Dis.* 2012; **206** Suppl 1: S129–35.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- <https://ourworldindata.org/covid-vaccinations?country=GMB> Accessed 08 July 2022.
- Tempia S, Walaza S, Bhiman JN, *et al.*: **Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020.** *Euro Surveill.* 2021; **26**(29): 2001600.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ntagereka PB, Basengere RA, Baharanyi TC, *et al.*: **Molecular Evidence of Coinfection with Acute Respiratory Viruses and High Prevalence of SARS-CoV-2 among Patients Presenting Flu-Like Illness in Bukavu City, Democratic Republic of Congo.** *Can J Infect Dis Med Microbiol.* 2022; **2022**: 1553266.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- El-Heneidy A, Ware RS, Robson JM, *et al.*: **Respiratory virus detection during the COVID-19 pandemic in Queensland, Australia.** *Aust N Z J Public Health.* 2022; **46**(1): 10–15.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cheemarla NR, Watkins TA, Mihaylova VT, *et al.*: **Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early**

## Data availability

### Underlying data

Open Science Framework: Circulation of respiratory viruses during the COVID-19 pandemic in the Gambia, <https://doi.org/10.17605/OSF.IO/TSF78><sup>18</sup>.

This project contains the following underlying data:

- EXTENDED DATA 2.xlsx (RT-PCR results for respiratory viruses detected from Fajara, Keneba and PaTS)

### Extended data

Open Science Framework: Circulation of respiratory viruses during the COVID-19 pandemic in the Gambia, <https://doi.org/10.17605/OSF.IO/TSF78><sup>18</sup>.

This project contains the following extended data:

- EXTENDED DATA 1\_TdS.docx (Table S1. Respiratory viruses detected during the study period stratified by age of participants for Fajara site)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

## Acknowledgements

We would like to acknowledge all participants and their families who agreed to take part in the study. We would also like to acknowledge the contributions from Chiquita Jones, Mary Grey Johnson, Catherine Sarr and Fatoumatta Sillah in recruiting participants to the PaTS trial.

- replication kinetics. *J Exp Med.* 2021; **218**(8): e20210583.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Dee K, Goldfarb DM, Haney J, *et al.*: **Human Rhinovirus Infection Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium: Implications for COVID-19 Epidemiology.** *J Infect Dis.* 2021; **224**(1): 31–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  16. Nickbakhsh S, Mair C, Matthews L, *et al.*: **Virus-virus interactions impact the population dynamics of influenza and the common cold.** *Proc Natl Acad Sci U S A.* 2019; **116**(52): 27142–27150.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  17. Wu A, Mihaylova VT, Landry ML, *et al.*: **Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study.** *Lancet Microbe.* 2020; **1**(6): e254–e62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  18. Jarju S, Senghore E, Brotherton H, *et al.*: **Circulation of respiratory viruses during the COVID-19 pandemic in the Gambia.** [Dataset] 2022.  
<http://www.doi.org/10.17605/OSF.IO/TSF78>

## Open Peer Review

Current Peer Review Status:  

### Version 1

Reviewer Report 27 January 2023

<https://doi.org/10.21956/gatesopenres.15460.r32799>

© 2023 Ho A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Antonia Ho** 

Medical Research Council-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK

For transparency, I have reviewed this manuscript for a different journal in September 2022. I note the authors have incorporated most of my suggested edits. This is therefore an update of the original review.

This study reports the prevalence of respiratory viruses across different age groups from nasopharyngeal swabs collected by 2 studies in The Gambia: i) ILI surveillance at an urban and a rural outpatient clinic; ii) a clinical trial of COVID-19 treatment based in urban and peri-urban areas. Existing studies that have evaluated respiratory viral circulation during the COVID-19 pandemic have predominantly been conducted in temperate settings; the majority have shown substantial reduction in activity of most respiratory viruses, which have been attributed to the strict implementation of non-pharmacological interventions.

Data on the circulation of respiratory viruses other than SARS-CoV-2 outside of high-income, temperate settings are scarce. Hence, data presented in this study are important. Similar to many African countries, Gambia imposed NPIs during the first pandemic wave (June to September 2020), but have not enforced NPIs since. Limited pre-pandemic data show that influenza circulated during the rainy season in the Gambia.

The authors identified high virus positivity (44.2%) among individuals presenting with ILI between April 2020-March 2022, especially in children <5 years (80%), compared to older age groups (39.5% in 18-50s & 39.9% in >50 years). SARS-CoV-2 was the most frequently detected virus, with higher prevalence in adult age groups, while rhinovirus, RSV and hMPV were more frequently detected in children. Influenza A circulated in September to December in 2020 and 2021, asynchronously to SARS-CoV-2, while influenza B was only identified in 2020. Another interesting finding is that peaks in rhinovirus activity were also asynchronous to SARS-CoV-2 waves, mirroring recent observations from laboratory studies.

The manuscript is well written, and contains important data. It has a number of limitations, i.e. limited demographic and clinical data, differing recruitment periods and eligibility criteria. The latter points are acknowledged by the authors.

Comments:

1. Local SARS-CoV-2 and influenza vaccination policy should be stated in the Methods.
2. More detail on the PaTS trial should be included. It is an RCT comparing Ivermectin vs. aspirin vs. placebo. Were samples included from participants from both cohorts 1 and 2?
3. The sampling strategy of ILI surveillance (study 1) should be included; age criteria, target numbers per day/week, as number of included samples seems to vary greatly according to Figure 2.
4. Limited demographic/clinical data are included, presumably not collected by ILI surveillance. Co-morbidities and vaccination status would have been useful.
5. The manuscript highlights scarce data on respiratory viral circulation from Africa - and mentions data from South Africa (Tempia Eurosurveillance 2021) and Ntagereka (Infect Dis med Micro 2022), but should also include Loevinsohn *et al.* (2022<sup>1</sup>), which was published prior to this manuscript. This surveillance study in Zambia found a substantial decline in the prevalence of RSV and influenza in the first year of the pandemic, while an increase in the prevalence of rhino/enteroviruses and non-SARS-CoV-2 coronaviruses was observed after March 2020 (when SARS-CoV-2 emerged in Zambia), compared to 2019.

**References**

1. Loevinsohn G, Hamahuwa M, Hardick J, Sinywimaanzi P, et al.: Respiratory viruses in rural Zambia before and during the COVID-19 pandemic. *Trop Med Int Health*. 2022; **27** (7): 647-654  
[PubMed Abstract](#) | [Publisher Full Text](#)

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Respiratory viral epidemiology.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 08 Feb 2023

**Sheikh Jarju**, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia

**Comments:**

**1. Local SARS-CoV-2 and influenza vaccination policy should be stated in the Methods.**

We agree that it is important to highlight the local SARS-CoV-2 and influenza vaccination policy. In the Gambia Government national deployment and vaccination plan for COVID-19 vaccines, priority groups are highlighted that includes health personnel, community workers, older people of age 65 years and above and people with pre-existing conditions would be considered for vaccination first, in that order (**The Gambia Government, 2020; The Republic of the Gambia national deployment and vaccination plan for COVID-19; Banjul**). We have now referenced this document.

However, there is no influenza vaccine policy in The Gambia, which we state in the methods.

**More detail on the PaTS trial should be included. It is an RCT comparing Ivermectin vs. aspirin vs. placebo. Were samples included from participants from both cohorts 1 and 2?**

The samples from PaTS included in this study were those initially screened to qualify for subsequent recruitment into cohort 1 or 2. This was at the initial stage of the study. Following successful screening and 2<sup>nd</sup> consenting to join the study, samples were then followed up and as per severity of conditions, they were then distributed into cohort 1 or 2.

We only stopped at the screening level and didn't include samples that were already in cohort 1 or 2. We have tried to make this clearer in the methods.

**2. The sampling strategy of ILI surveillance (study 1) should be included; age criteria, target numbers per day/week, as number of included samples seems to vary greatly according to Figure 2.**

The ILI surveillance (study 1) recruited all age groups. We recruited all participants that fulfilled the case definition in a day/week and were willing to participate in the study. We have added some text to the methods to make this clearer. The fluctuation in numbers could be due to a number of reasons, but most likely due to the number of patients presenting with ILI.

**3. Limited demographic/clinical data are included, presumably not collected by ILI surveillance. Co-morbidities and vaccination status would have been useful.**

We agree that these aspects would be interesting. Unfortunately, we do not have extensive and systematically collected data on these variables from all the various data sources included in this ILI study.

**4. The manuscript highlights scarce data on respiratory viral circulation from Africa - and mentions data from South Africa (Tempia Eurosurveillance 2021) and Ntagereka (Infect Dis med Micro 2022), but should also include Loevinsohn et al. (20221), which was published prior to this manuscript. This surveillance study in Zambia found a substantial decline in the prevalence of RSV and influenza in the first year of the pandemic, while an increase in the prevalence of rhino/enteroviruses and non-SARS-CoV-2 coronaviruses was observed after March 2020 (when SARS-CoV-2 emerged in Zambia), compared to 2019.**

We agree that the Zambia paper is an important publication to reference in our manuscript and have discussed this paper.

**Competing Interests:** no competing interest

Reviewer Report 18 January 2023

<https://doi.org/10.21956/gatesopenres.15460.r32800>

© 2023 Asante I. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Ivy A. Asante** 

Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

In this paper, the authors describe their observations concerning respiratory pathogens during the COVID-19 pandemic in The Gambia. The data they describe is very important especially from West Africa where such data is not readily available.

Comments:

1. From Figure 1, it looks like the authors looked at some selected sites in The Gambia, as opposed to the whole country. Even if sites were few and distributed throughout the country, it would be said to represent the country. For consideration, the authors could include 'selected sites in The Gambia' in their title.
2. The authors used a multiplex RT-PCR assay that detected a panel of respiratory pathogens. This detection however did not distinguish or sub-type viruses seen. E.g. for influenza B,

lineage determination was not reported, same for influenza A and the human coronaviruses. If this data is available, it should be included.

3. Specify what UTM was used. What is the volume of the Universal transport medium? Why did the researchers choose to collect only NP swabs and not a combined OP/NP swab?
4. For the ILI surveillance system, is there a systematic approach to sample collection? E.g. A specific number expected each week? This could explain the number of samples tested during each of the months; what accounted for the high number of samples in one month and a low number in another?
5. Is the SARS-CoV-2 data observed in this study comparable to national data? It is not very clear.
6. Was there any correlation between detection of SARS-CoV-2 and other respiratory viruses?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Virology, surveillance for respiratory viruses

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 08 Feb 2023

**Sheikh Jarju**, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia

Comments:

**1. From Figure 1, it looks like the authors looked at some selected sites in The Gambia, as opposed to the whole country. Even if sites were few and distributed throughout the country, it would be said to represent the country. For consideration, the authors could include 'selected sites in The Gambia' in their title.**

We appreciate the reviewer's point that the study only included data from limited sites. The sites selected represented both an urban and rural settlement of the country and many people seek medical care in the urban clinics we have included from different part of the country. We have discussed these limitations but feel that we do not need to change the title of the manuscript.

**2. The authors used a multiplex RT-PCR assay that detected a panel of respiratory pathogens. This detection however did not distinguish, or sub-type viruses seen. E.g., for influenza B, lineage determination was not reported, same for influenza A and the human coronaviruses. If this data is available, it should be included.**

We agree with the suggestion that lineage information, for example influenza virus, would have added an additional information. Unfortunately, we do not have this data as all seasonal coronaviruses were detected on one probe. We do, however, have a specific H1N1 assay and what we report are influenza A data stratified by whether they were positive in the influenza A assay alone (which would pick up both H3N2 and H1N1) or in both this assay and the H1N1 specific assay. This is stated in the table legends.

**3. Specify what UTM was used. What is the volume of the Universal transport medium? Why did the researchers choose to collect only NP swabs and not a combined OP/NP swab?**

We did use UTM Copan 360C with 1ml medium. This has been added to the methods. We used nasopharyngeal swabs as the method of choice due to the extensive experience in our field teams in NPS collection during many studies of viral and bacterial carriage.

**4. or the ILI surveillance system, is there a systematic approach to sample collection? E.g. A specific number expected each week. This could explain the number of samples tested during each of the months; what accounted for the high number of samples in one month and a low number in another?**

We have included a statement about this in response to a comment from reviewer 1 in the methods. We attempted to recruit everyone who fulfilled the case definition and was willing to participate in the study.

**5. Is the SARS-CoV-2 data observed in this study comparable to national data? It is not very clear.**

Yes, the SARS-CoV-2 data observed in our study is comparable with the national data. We have stated this and added a reference.

**6. Was there any correlation between detection of SARS-CoV-2 and other respiratory**

## **viruses?**

No clear correlations are present. We have reported the number of co-infections and also highlighted the potential viral interference observed between SARS-CoV-2, influenza and human rhinoviruses in terms of the peaks observed. This is included in the discussion already.

**Competing Interests:** no competing interest

---